Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 10/μL after 7 days of treatment with RFP, isoniazid, ethambutol, and pyrazinamide. After all the drugs were discontinued, the platelet count recovered. As thrombocytopenia did not occur after re-administration of drugs other than RFP, the patient was diagnosed with RFP-induced thrombocytopenia. Clinicians should be aware that RFP can induce acute and severe thrombocytopenia even without previous exposure to this drug.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006502PMC
http://dx.doi.org/10.1016/j.rmcr.2023.101823DOI Listing

Publication Analysis

Top Keywords

severe thrombocytopenia
12
thrombocytopenia exposure
8
platelet count
8
thrombocytopenia
6
rfp
5
case severe
4
exposure rifampicin
4
rifampicin severe
4
severe immune
4
immune thrombocytopenia
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!